Single Dose G1090N + Multiple dosing of G1090N
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute-on-Chronic Liver Failure
Conditions
Acute-on-Chronic Liver Failure
Trial Timeline
Aug 26, 2025 → Dec 3, 2025
NCT ID
NCT07110441About Single Dose G1090N + Multiple dosing of G1090N
Single Dose G1090N + Multiple dosing of G1090N is a phase 1 stage product being developed by Genfit for Acute-on-Chronic Liver Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT07110441. Target conditions include Acute-on-Chronic Liver Failure.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07110441 | Phase 1 | Completed |
Competing Products
2 competing products in Acute-on-Chronic Liver Failure
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SMT + PE-A 5% | Grifols | Phase 3 | 74 |
| VS-01 on top of SOC | Genfit | Phase 2 | 44 |